RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cristina Cruz(Vall d'Hebron Institut de Recerca), Violeta Serra(Vall d'Hebron Institute of Oncology), José Baselga(Novartis (Switzerland)), Zhongwu Lai(AstraZeneca (United States)), L.D. Bustos, José Jimenez(Molecular Oncology (United States)), Albert Gris‐Oliver, Petra Kristel(The Netherlands Cancer Institute), Gemma N. Jones(AstraZeneca (United Kingdom)), Ginevra Caratù(Cancer Genomics Centre), Judit Grueso(University of North Carolina at Chapel Hill), Francesco M. Mancuso(Cancer Genomics Centre), Urszula M. Polanska(AstraZeneca (United Kingdom)), Gemma Montalban, Isabel T. Rubio(Clinica Universidad de Navarra), Elaine Cadogan(AstraZeneca (Singapore)), Roberta Fasani(Vall d'Hebron Institute of Oncology), J. Carl Barrett(National Institute of Environmental Health Sciences), Olga Rodríguez(University of North Carolina at Chapel Hill), Javier Cortés(Villa Maria Hospital), Xavier Serres, Mark J. O’Connor(AstraZeneca (United Kingdom)), Jos Jonkers(The Netherlands Cancer Institute), Sara Gutiérrez‐Enríquez, Ana Oaknin(Hebron University), Alba Llop‐Guevara(Vall d'Hebron Institut de Recerca), Alejandra Bruna(Institute of Cancer Research), Ana Vivancos(Vall d'Hebron Institute of Oncology), William Howat(AstraZeneca (United Kingdom)), Marta Castroviejo‐Bermejo, Joaquı́n Arribas(Hospital Del Mar), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Cristina Saura(Vall d'Hebron Hospital Universitari), Judith Balmañà(Vall d'Hebron Hospital Universitari), Sandra Bonache, Marta Guzmán(University of North Carolina at Chapel Hill), Beatriz Morancho(Vall d'Hebron Institut de Recerca), Brian Dougherty(AstraZeneca (United States)), Carlos Caldas(University of Cambridge), Orland Dı́ez(Vall d'Hebron Hospital Universitari), Yasir H. Ibrahim(Royal National Orthopaedic Hospital), Oscar M. Rueda(University of Cambridge)
Cited by 424
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k